Relevant bibliographies by topics / Tumour active

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Tumour active'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Tumour active.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Tumour active"

1

Keln, A. A., S. S. Schmidt, A. V. Kupchin, and B. A. Berdichevsky. "Active monitoring of contrast-accumulating kidney tumours." Urology Herald 8, no. 4 (2020): 53–61. http://dx.doi.org/10.21886/2308-6424-2020-8-4-53-61.

Full text
Abstract:
Introduction. The incidence of kidney cancer (KC) in the world is increasing and today is about 3%, but the death rate from this type of malignancy does not increase proportionally. According to research by many authors, more than half of the patients are over 65 years old at the time of diagnosis. Patients at this age have a high incidence of high comorbidity and risk of death from cardiovascular or other intercurrent pathology that exceeds the risk of death from KC. Recently, there has been a positive trend in the detection of the disease in the early stages up to 61.80%. Most of the primary
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Tumour-specific superantigens - super active." Inpharma Weekly &NA;, no. 896 (1993): 12. http://dx.doi.org/10.2165/00128413-199308960-00026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sagnella, Sharon M., Joshua A. McCarroll, and Maria Kavallaris. "Drug delivery: Beyond active tumour targeting." Nanomedicine: Nanotechnology, Biology and Medicine 10, no. 6 (2014): 1131–37. http://dx.doi.org/10.1016/j.nano.2014.04.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bucella, Dario, Jean-Frédéric Limbosch, Frédéric Buxant, et al. "Recurrence of Mitotically Active Cellular Fibroma of the Ovary." Obstetrics and Gynecology International 2009 (2009): 1–3. http://dx.doi.org/10.1155/2009/803062.

Full text
Abstract:
Background. 10% of ovarian fibromatous tumours typically exhibit increased cellularity, mitotic activity, and less frequently nuclear atypia. Therefore, the classification within the group of fibromatous tumours may represent some difficulties, thus, one or several of these features should appear.Case. We introduce the clinical and pathologic features based on one case of recurrence of a mitotically active cellular ovarian fibroma (MACF) in the pararectal fossa. This recurrence took place six years after primary surgery. Macroscopically, the tumour was firm, fibrous, well delimited, yellow-whi
APA, Harvard, Vancouver, ISO, and other styles
5

Shankar Dey, Bhabani, Manas Kumar Bera, and Binoy Krishna Roy. "Nonlinear active control of a cancerous tumour." International Journal of Engineering & Technology 7, no. 2.21 (2018): 72. http://dx.doi.org/10.14419/ijet.v7i2.21.11839.

Full text
Abstract:
This paper deals with the control of a cancerous tumour growth. The model used is a Three-Dimensional Cancer Model (TDCM). The competition terms include tumour cells, healthy cells, and immune cells. Nature of the competition among the populations of tumour cells, healthy host cells, and immune cells results in a chaotic behaviour. In this paper, a nonlinear active control has been used to control the growth of a tumour. Effect of chemotherapy drug on the different cell populations has been studied. Our control objective is to control the tumour growth and minimize its population to a small va
APA, Harvard, Vancouver, ISO, and other styles
6

Hirsjarvi, Samuli, Catherine Passirani, and Jean-Pierre Benoit. "Passive and Active Tumour Targeting with Nanocarriers." Current Drug Discovery Technologies 8, no. 3 (2011): 188–96. http://dx.doi.org/10.2174/157016311796798991.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Salmaso, Stefano, Sara Bersani, Alessandra Semenzato, and Paolo Caliceti. "New cyclodextrin bioconjugates for active tumour targeting." Journal of Drug Targeting 15, no. 6 (2007): 379–90. http://dx.doi.org/10.1080/10611860701349752.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Yan, Hengkang, Mary E. Vail, Linda Hii, et al. "Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours." Cancers 14, no. 13 (2022): 3171. http://dx.doi.org/10.3390/cancers14133171.

Full text
Abstract:
ADAM10 is a transmembrane metalloprotease that sheds a variety of cell surface proteins, including receptors and ligands that regulate a range of developmental processes which re-emerge during tumour development. While ADAM10 is ubiquitously expressed, its activity is normally tightly regulated, but becomes deregulated in tumours. We previously reported the generation of a monoclonal antibody, 8C7, which preferentially recognises an active form of ADAM10 in human and mouse tumours. We now report our investigation of the mechanism of this specificity, and the preferential targeting of 8C7 to hu
APA, Harvard, Vancouver, ISO, and other styles
9

O'Rourke, N. P., E. V. McCloskey, and J. A. Kanis. "Tumour induced hypercalcaemia: A case for active treatment." Clinical Oncology 6, no. 3 (1994): 172–76. http://dx.doi.org/10.1016/s0936-6555(94)80057-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Herrmann, Th. "Radiation oncology and functional imaging." Nuklearmedizin 44, S 01 (2005): S38—S40. http://dx.doi.org/10.1055/s-0038-1625213.

Full text
Abstract:
Summary:PET/CT imaging is most likely to be of use in radiation oncology with patients who have poorly defined target volume areas, e.g. brain tumours, bronchogenic carcinoma, and cases of miscellaneous geographical miss. Other tumours that call for dose escalated radiotherapy, such as head and neck tumours, bronchogenic carcinoma, and prostate carcinomas may further benefit from an accurate delineation of the metabolically active tumour volume and its differentiation from surrounding healthy tissue, or tumour atelectasis.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Tumour active"

1

Daghriri, Hassan. "Studies on Tumour Active Compounds with Multiple Metal Centres." University of Sydney. Biomedical Sciences, 2004. http://hdl.handle.net/2123/595.

Full text
Abstract:
Four tumour active trinuclear complexes: DH4Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)4NH2)2]Cl4, DH5Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)5NH2)2]Cl4, DH6Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)6NH2)2]Cl4, DH7Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd(NH3)2-( H2N(CH2)7NH2)2]Cl4 and one dinuclear complex DHD: [{trans-PtCl(NH3)2}�-{ H2N(CH2)6NH2}{trans-PdCl(NH3)2]Cl(NO3), have been prepared and characterised based on elemental analyses, IR, Raman, mass and 1 H NMR spectral measurements. For the trinuclear complexes, the synthesis has been carried out using a step
APA, Harvard, Vancouver, ISO, and other styles
2

Daghriri, Hassan. "Studies on Tumour Active Compounds with Multiple Metal Centres." Thesis, The University of Sydney, 2003. http://hdl.handle.net/2123/595.

Full text
Abstract:
Four tumour active trinuclear complexes: DH4Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)4NH2)2]Cl4, DH5Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)5NH2)2]Cl4, DH6Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd( NH3)2(H2N(CH2)6NH2)2]Cl4, DH7Cl: [{trans-PtCl(NH3)2}2m-{trans-Pd(NH3)2-( H2N(CH2)7NH2)2]Cl4 and one dinuclear complex DHD: [{trans-PtCl(NH3)2}�-{ H2N(CH2)6NH2}{trans-PdCl(NH3)2]Cl(NO3), have been prepared and characterised based on elemental analyses, IR, Raman, mass and 1 H NMR spectral measurements. For the trinuclear complexes, the synthesis has been carried out using a step
APA, Harvard, Vancouver, ISO, and other styles
3

Tayyem, Hasan. "Studies on new tumour active compounds with one or more metal centres." zConnect to full text, 2006. http://hdl.handle.net/2123/1727.

Full text
Abstract:
Thesis (Ph. D.)--University of Sydney, 2007.<br>Title from title screen (viewed may 17, 2007). Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy to the School of Biomedical Sciences, Faculty of Health Sciences. Degree awarded 2007; thesis submitted 2006. Includes bibliographical references. Also issued in print.
APA, Harvard, Vancouver, ISO, and other styles
4

Tayyem, Hasan Mohammad. "Studies on new tumour active compounds with one or more metal centres." Thesis, The University of Sydney, 2006. http://hdl.handle.net/2123/1727.

Full text
Abstract:
The present study deals with the synthesis, characterization, determination of anticancer activity of three mononuclear trans-planaraminepalladium(II) complexes code named TH5, TH6 and TH7 and three trinuclear complexes code named TH1, TH8 and TH14. The activity of the compounds against human cancer cell lines: A2780, A2780cisR and A2780ZD0473R, cell uptake, DNA-binding and nature of interaction with pBR322 plasmid DNA have been determined. Whereas cisplatin binds with DNA forming mainly intrastrand GG adduct that causes local bending of a DNA strand, TH5, TH6, TH7, TH1 and TH8 bind with DNA f
APA, Harvard, Vancouver, ISO, and other styles
5

Tayyem, Hasan Mohammad. "Studies on new tumour active compounds with one or more metal centres." Faculty of Health Sciences, 2006. http://hdl.handle.net/2123/1727.

Full text
Abstract:
Doctor of Philosophy(PhD)<br>The present study deals with the synthesis, characterization, determination of anticancer activity of three mononuclear trans-planaraminepalladium(II) complexes code named TH5, TH6 and TH7 and three trinuclear complexes code named TH1, TH8 and TH14. The activity of the compounds against human cancer cell lines: A2780, A2780cisR and A2780ZD0473R, cell uptake, DNA-binding and nature of interaction with pBR322 plasmid DNA have been determined. Whereas cisplatin binds with DNA forming mainly intrastrand GG adduct that causes local bending of a DNA strand, TH5, TH6, TH7
APA, Harvard, Vancouver, ISO, and other styles
6

Subbotina, Beztsinna Nataliia. "Riboflavin-based amphiphiles for tumour-targeted nanosystems." Thesis, Bordeaux, 2015. http://www.theses.fr/2015BORD0254/document.

Full text
Abstract:
La riboflavine (RF) est une vitamine essentielle pour la croissance et le développement cellulaire. Elle possède des propriétés physico-chimiques intéressantes et est internalisée dans les cellules par des transporteurs spécifiques. Le premier objectif de ce projet était de synthétiser des dérivés amphiphiles de la RF (RFA) et d'étudier leurs capacités d'auto-assemblages. Le second objectif était d'insérer les RFA dans des liposomes et d'évaluer leur efficacité de ciblage tumoral in vitro et in vivo. La préparation des différents RFA repose sur l'ajout d'un lipide en différentes positions de l
APA, Harvard, Vancouver, ISO, and other styles
7

Lavaud, Mélanie. "Identification des acteurs clés impliqués dans le développement du tissu osseux et l'évolution des ostéosarcomes par études des super-enhancers actifs." Thesis, Nantes Université, 2022. http://www.theses.fr/2022NANU1019.

Full text
Abstract:
Les super-enhancers (SE) correspondent à des groupement d'enhancers qui recrutent le complexe transcriptionnel pour induire la transcription de leurs gènes cibles plus efficacement que les enhancers. Ils régulent des gènes clés définissant l'identité cellulaire dans des conditions physiologiques et pathologiques. Les objectifs de ce projet de thèse étaient de caractériser le développement osseux normal par l'étude des gènes clés de l'ostéoblastogenèse et de l'ostéoclastogenèse et de caractériser l'évolution métastatique de l'ostéosarcome (OS), la tumeur osseuse primitive maligne la plus fréque
APA, Harvard, Vancouver, ISO, and other styles
8

Milbank, Edward. "Extracellular vesicles as a therapeutic strategy to prevent or reverse obesity and its metabolic complications in the field of nanomedicine Extracellular vesicles: Pharmacological modulators of the peripheral and central signals governing obesity Microparticles from apoptotic RAW 264.7 macrophage cells carry tumour necrosis factor-a functionally active on cardiomyocytes from adult mice." Thesis, Angers, 2016. http://www.theses.fr/2016ANGE0074.

Full text
Abstract:
A ce jour, les thérapies anti-obésité restent limitées. De récente études ont fourni des résultats prometteurs en démontrant une diminution du poids de la souris via une injection stéréotaxique d’une forme dominante négative de l’AMPK (AMPK DN) directement dans le noyau ventromédial hypothalamique (VMH). Cependant, le potentiel thérapeutique de cette thérapie génique se voit entravé par une libération non spécifique de l’AMPK suite à une injection intraveineuse, plus adaptée à une approche clinique. Nous avons donc développé une approche de « nanobiomédecine » en utilisant des exosomes - nanov
APA, Harvard, Vancouver, ISO, and other styles
9

Barbara, Jeffrey A. J. "The mechanism of action of tumour necrosis factor-[alpha] /." Title page, contents and abstract only, 1995. http://web4.library.adelaide.edu.au/theses/09PH/09phb229.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Roelofs, Anke. "Anti-tumour mechanisms of action bisphosphonates and bisphosphonate analogues." Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.436994.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Tumour active"

1

Kushida, Michelle Mayumi. Identification of CIS-active targets of MHC class 1 transcritional downregulaton in tumour cells. National Library of Canada, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bates, P. I. Radiosynthesis and biological studies with platinum and carbon labelled JM216: An orally active platinum anti-tumour complex. UMIST, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Orentas, Rimas. Cancer vaccines and tumor immunity. Wiley-Interscience, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

service), SpringerLink (Online, ed. Innate and Adaptive Immunity in the Tumor Microenvironment. Springer Science + Business Media, LLC, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ilgren, E. B. Mesotheliomas of animals: A comprehensive, tabular compendium of the world's literature. CRC Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1950-, Morstyn George, Foote MaryAnn, and Lieschke Graham J, eds. Hematopoietic growth factors in oncology: Basic science and clinical therapeutics. Humana Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

C, Dale David, and SpringerLink (Online service), eds. Hematopoietic Growth Factors in Oncology. Springer Science+Business Media, LLC, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gen, Sobue, and New York Academy of Sciences, eds. Integrated molecular medicine for neuronal and neoplastic disorders. Blackwell Pub. on behalf of the New York Academy of Sciences, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tamoxifen: Molecular basis of use in cancer treatment and prevention. J. Wiley & Sons, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

L, Spitzer Hugh, ed. Receptor-mediated biological processess: Implications forevaluating carcinogenesis : proceedings of the Sixth International Conference on Carcinogenesis and Risk Assessment, held in Austin, Texas, on December 8-11, 1992. Wiley-Liss, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Tumour active"

1

Gardiner, K. R., M. I. Halliday, F. Lloyd, S. Stephens, and B. J. Rowlands. "Circulating Tumour Necrosis Factor in Active Inflammatory Bowel Disease." In Host Defense Dysfunction in Trauma, Shock and Sepsis. Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-77405-8_90.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rotomskis, R. "Primary Photoprocesses in Biologically Active Pigments Related to Photosensitized Tumour Therapy." In Ultrafast Processes in Spectroscopy. Springer US, 1996. http://dx.doi.org/10.1007/978-1-4615-5897-2_113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Burdon, R. H. "Cellularly generated active oxygen species as signals in the activation of tumour cell growth." In Oxidative Stress, Cell Activation and Viral Infection. Birkhäuser Basel, 1994. http://dx.doi.org/10.1007/978-3-0348-7424-3_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dietz, C., J. S. Becker, S. Hennig, V. Welter, I. Celik, and D. K. Bartsch. "Inhibition of the enzyme Dihydroorotate Dehydrogenase by Leflunomid and the active metabolite A 771726 inhibits in vitro tumour cell proliferation and in vivo tumour growth in pancreatic carcinoma SCID mouse model." In Deutsche Gesellschaft für Chirurgie. Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-00625-8_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Maraveyas, A., and A. G. Dalgleish. "Active Immunotherapy for Solid Tumours." In Vaccine Design. Springer US, 1997. http://dx.doi.org/10.1007/978-1-4899-0062-3_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cerutti, Peter A. "Active Oxygen and Promotion." In Arachidonic Acid Metabolism and Tumor Promotion. Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2605-2_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Leppien, G., G. Dallenbach-Hellweg, T. Rabe, and B. Runnebaum. "Hormonal Active Ovarian Tumors." In Gynecological Endocrinology and Reproductive Medicine. Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60390-7_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Patel, Hiten D., and Phillip M. Pierorazio. "Active Surveillance of Renal Tumors." In Diagnosis and Surgical Management of Renal Tumors. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92309-3_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Weber, Sharon M., and Fred T. Lee. "Cryoablation: History, Mechanism of Action, and Guidance Modalities." In Tumor Ablation. Springer New York, 2005. http://dx.doi.org/10.1007/0-387-28674-8_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Todaro, George J. "Tumor Growth Factors." In Molecular Basis of Lymphokine Action. Humana Press, 1987. http://dx.doi.org/10.1007/978-1-4612-4598-8_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Tumour active"

1

Vepřek, Pavel, Kateřina Knytlová, Miroslav Ledvina, Tomáš Trnka, and Jan Ježek. "The preparation of multivalent peptide and glycopeptide dendrimers bearing Tn tumour antigens." In VIIth Conference Biologically Active Peptides. Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2001. http://dx.doi.org/10.1135/css200104017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kot, Estera, Zuzanna Krawczyk, Krzysztof Siwek, and Piotr S. Czwarnowski. "U-Net and Active Contour Methods for Brain Tumour Segmentation and Visualization." In 2020 International Joint Conference on Neural Networks (IJCNN). IEEE, 2020. http://dx.doi.org/10.1109/ijcnn48605.2020.9207572.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zeng, Ziming, Jue Wang, Tony Shepherd, and Reyer Zwiggelaar. "Region-based active surface modelling and alpha matting for unsupervised tumour segmentation in PET." In 2012 19th IEEE International Conference on Image Processing (ICIP 2012). IEEE, 2012. http://dx.doi.org/10.1109/icip.2012.6467280.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ziming Zeng, T. Shepherd, and R. Zwiggelaar. "Unsupervised tumour segmentation in PET based on local and global intensity fitting active surface and alpha matting." In 2012 34th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2012. http://dx.doi.org/10.1109/embc.2012.6346432.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Boki, KA, VA Vassiliou, G. Linardaki, and HM Moutsopoulos. "FRI0060 Successful treatment of active rheumatoid arthritis with chimeric monoclonal antibody to tumour necrosis factor (infliximab): an open study." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.1189.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Coates, LC, P. Mease, ME Husni, et al. "FRI0502 Ixekizumab reduces disease activity in active psoriatic arthritis patients who had previous inadequate response to tumour necrosis factor-inhibitors." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.2757.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kavanaugh, A., R. Vender, J. Birt, et al. "SAT0446 Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.1580.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Descriptive Epidemiological Study of Colorectal Cancer Patients at a Tertiary Hospital in North Jordan." In International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/wyzq8668.

Full text
Abstract:
Introduction and Aim Colorectal cancer (CRC) incidences have been steadily on the rise and is one of the common cancers worldwide; it accounted for 10.7% of all new cancer incidences in 2016 in Jordan. We aim to describe epidemiological, demographical, and clinical characteristics of CRC in North Jordan. Methods A single-center retrospective review of all patients diagnosed with CRC between 2003 and 2019 at King Abdullah University Hospital (KAUH) in Irbid, North of Jordan was performed. Clinical and demographical data were extracted from the patients’ medical records. Patients were stratified
APA, Harvard, Vancouver, ISO, and other styles
9

Merola, J. F., P. Rich, J. P. Dutz, D. Adams, L. Kerr, and L. E. Kristensen. "THU0313 Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.2347.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nash, P., B. Kirkham, M. Okada, et al. "OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.1576.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Tumour active"

1

Vazquez, Francisca. Regulation of the PTEN Tumor Suppressor: Identification of the Active Protein Complex. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada429196.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zacksenhaus, Eldad. Dominant-Active Alleles of Rb as Universal Tumor Suppressors of Mammary Carcinoma. Defense Technical Information Center, 1999. http://dx.doi.org/10.21236/ada382540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhan, Xi. The Role of Actin Polymerization in Tumor Metastasis. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada431324.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhan, Xi. The Role of Actin Polymerization in Tumor Metastasis. Defense Technical Information Center, 2002. http://dx.doi.org/10.21236/ada411545.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zhan, Xi. The Role of Actin Polymerization in Tumor Metastasis. Defense Technical Information Center, 2003. http://dx.doi.org/10.21236/ada420763.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, Jiing-Dwan. Molecular Action of a Potential Tumor Suppression in Mammary Carcinogenesis. Defense Technical Information Center, 2006. http://dx.doi.org/10.21236/ada456140.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wang, Lizhong. Synergistic Action of FOXP3 and TSC1 Pathways During Tumor Progression. Defense Technical Information Center, 2015. http://dx.doi.org/10.21236/ada625959.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gail A. Bishop, Gail A. Bishop. Using Nanoparticles to Activate Immune Cells to Fight Tumors. Experiment, 2014. http://dx.doi.org/10.18258/3518.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Inoue, Takashi, and Mamoru Narukawa. Anti-tumor efficacy of anti-PD-1/PD-L1 antibodies in combination with other anticancer drugs in solid tumors: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.10.0004.

Full text
Abstract:
Review question / Objective: The aim of this systematic review is to compare the combination of PD-1/PD-L1 inhibitors plus other anticancer drugs and monotherapies of PD-1/PD-L1 inhibitors in terms of antitumor efficacy in the solid tumors to better inform clinical practice. To this end, the proposed systematic review will address the following question: Which is the best choice to enhance response rate in subjects with solid tumors, PD-1/PD-L1 inhibitors plus cytotoxic agents or PD-1/PD-L1 inhibitors plus other targeted anticancer drugs? Condition being studied: Cancer is the leading cause of
APA, Harvard, Vancouver, ISO, and other styles
10

Ramesh, Vijaya. Neurofibromatosis 2 Tumor Suppressor Protein, Merlin, in Cellular Signaling to Actin Cytoskeleton. Defense Technical Information Center, 2000. http://dx.doi.org/10.21236/ada395581.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Tumour active' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography